Aprovix is a medical technology company with its registered office in Uppsala, north of Stockholm, Sweden. Aprovix was founded in 2001, based on an idea by Professor Erik Wilander of Uppsala.
His basic idea was to offer a new health-check method to women that are not participating in organized smear test programs based on self-sampling followed by HPV tests. Professor Wilander associated with a group of researchers and business developers to transform his idea into a finished product. After several years of planning, testing and evaluation, this product was created: Qvintip.
Qvintip can supply healthcare providers with a tailored, cost-effective and reliable self sampling process combined with HPV testing for early detection of pre-stages of cervical cancer.
After developing the concept and process, testing and validating it for four years in Uppsala county Aprovix is now ready to offer the process, concept and self sampling device to distributors in Europe and Middle East who want to set up the process and offer it to healthcare providers in their respective markets.
Our vision is to reduce suffering and deaths caused by cervical cancer using HPV home testing. Today, Qvintip has been used by over 100 000 women.
Clinical Trials with a Positive Outcome
Aprovix started its first clinical trials on Qvintip at Uppsala University Hospital in 2006. More than 7,500 women participated in the trials in 2006‐2010, over 3,600 of them using Qvintip. The results have been published in recognized medical journals. Some results stand out.
Please see the list of references for further documentation of the pilot projects with Qvintip.
With the pilots in Sweden completed the company now enters a new phase. The complete self sampling process including sampler, IT system to manage the process, operative processes has been “packaged” and Aprovix is now ready to offer the concept to companies in Europe and the Middle East.
HPV testing and cervical cancer are attracting major interest. The Nobel Prize in 2008 and a decisions to vaccinate girls against HPV has reinforced the understanding that cervical cancer can be prevented if effective health-checks are offered. In this context, Qvintip can satisfy the needs of health authorities and individual women.